Ming‐Yi Chiang
YOU?
Author Swipe
View article: Therapeutic treatment with PLGA nanoparticles containing a single CD4+ epitope reverses CD8+ T cell-induced type I diabetes disease progression 3303
Therapeutic treatment with PLGA nanoparticles containing a single CD4+ epitope reverses CD8+ T cell-induced type I diabetes disease progression 3303 Open
Description Autoimmune diseases, such as multiple sclerosis and type-1 diabetes (T1D), are mediated by autoantigen-specific CD4+ and CD8+ T cells. Treatment with antigen (Ag)-containing biodegradable poly(lactide-co-glycolide) (PLGA) nanop…
View article: <scp>AA147</scp> Alleviates Symptoms in a Mouse Model of Multiple Sclerosis by Reducing Oligodendrocyte Loss
<span>AA147</span> Alleviates Symptoms in a Mouse Model of Multiple Sclerosis by Reducing Oligodendrocyte Loss Open
Inflammation‐induced oligodendrocyte death and CNS demyelination are key features of multiple sclerosis (MS). Inflammation‐triggered endoplasmic reticulum (ER) stress and oxidative stress promote tissue damage in MS and in its preclinical …
View article: Allergen‐Encapsulating Nanoparticles Reprogram Pathogenic Allergen‐Specific Th2 Cells to Suppress Food Allergy
Allergen‐Encapsulating Nanoparticles Reprogram Pathogenic Allergen‐Specific Th2 Cells to Suppress Food Allergy Open
Food allergy is a prevalent, potentially deadly disease caused by inadvertent sensitization to benign food antigens. Pathogenic Th2 cells are a major driver for disease, and allergen‐specific immunotherapies (AIT) aim to increase the aller…
View article: Biodegradable Nanoparticles Immunotherapy for the Treatment of Carcinogen-Induced Bladder Cancer
Biodegradable Nanoparticles Immunotherapy for the Treatment of Carcinogen-Induced Bladder Cancer Open
Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1–17.8), with a 23% response rate to monotherapy treatment with anti-PD-L1 immunotherapy. We recently reported the potent e…
View article: Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma Open
The long-term survival of patients with advanced urothelial carcinoma (UCa) is limited because of innate resistance to treatment. We identified elevated expression of the histone methyltransferase EZH2 as a hallmark of aggressive UCa and h…
View article: Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy
Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy Open
Cancer treatment utilizing infusion therapies to enhance the patient’s own immune response against the tumor have shown significant functionality in a small subpopulation of patients. Additionally, advances have been made in the utilizatio…
View article: Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice
Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice Open
Type 1 diabetes (T1D) is an autoimmune disease characterized by T and B cell responses to proteins expressed by insulin-producing pancreatic β cells, inflammatory lesions within islets (insulitis), and β cell loss. We previously showed tha…
View article: Methodology for in vitro Assessment of Human T Cell Activation and Blockade
Methodology for in vitro Assessment of Human T Cell Activation and Blockade Open
Methods to test both the functionality and mechanism of action for human recombinant proteins and antibodies in vitro have been limited by multiple factors. To test the functionality of a recombinant protein or antibody, the receptor, the …
View article: Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma
Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma Open
Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1-17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1 checkpoint immunotherapy. To identify new th…
View article: Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell–Mediated Central Nervous System Autoimmune Disease
Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell–Mediated Central Nervous System Autoimmune Disease Open
Leukocyte trafficking into the CNS is a prominent feature driving the immunopathogenesis of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Blocking the recruitment of inflammatory leukocytes into the CN…